Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix for heavy menstrual bleeding associated with uterine fibroids (Phase III, China)
ChiCTR2500105579Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing Relugolix 40 mg with Placebo (2 arms). Primary endpoint: Menstrual blood loss. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on ChiCTR2500105579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105579.